Taysha Gene Therapies, Inc. Accumulated Other Comprehensive Income
Taysha Gene Therapies, Inc. (TSHA) had Accumulated Other Comprehensive Income of $769.00 thousand as of 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax · last filed 2026-08-11
- 2026-06-30: Accumulated Other Comprehensive Income (Loss), Net of Tax $769.00K.
- 2026-03-31: Accumulated Other Comprehensive Income (Loss), Net of Tax $985.00K.
- 2025-12-31: Accumulated Other Comprehensive Income (Loss), Net of Tax -$192.00K.
- 2025-09-30: Accumulated Other Comprehensive Income (Loss), Net of Tax -$1.14M.
| Period end | Accumulated Other Comprehensive Income (Loss), Net of Tax |
|---|---|
| 2026-06-30 | $769.00K 10-Q · filed 2026-08-11 |
| 2026-03-31 | $985.00K 10-Q · filed 2026-05-06 |
| 2025-12-31 | -$192.00K 10-Q · filed 2026-08-11 |
| 2025-09-30 | -$1.14M 10-Q · filed 2025-11-04 |
| 2025-06-30 | -$699.00K 10-Q · filed 2025-08-12 |
| 2025-03-31 | -$2.29M 10-Q · filed 2025-05-15 |
| 2024-12-31 | -$4.03M 10-K · filed 2026-03-19 |
| 2024-09-30 | -$2.33M 10-Q · filed 2024-11-13 |
| 2024-06-30 | $2.40M 10-Q · filed 2024-08-12 |
| 2024-03-31 | -$251.00K 10-Q · filed 2024-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |